First Time Loading...

Santen Pharmaceutical Co Ltd
TSE:4536

Watchlist Manager
Santen Pharmaceutical Co Ltd Logo
Santen Pharmaceutical Co Ltd
TSE:4536
Watchlist
Price: 1 569 JPY -1.81% Market Closed
Updated: May 21, 2024

Santen Pharmaceutical Co Ltd
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Santen Pharmaceutical Co Ltd
Income from Continuing Operations Peer Comparison

Comparables:
4502
4568
4578
4519
4503

Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Santen Pharmaceutical Co Ltd
TSE:4536
Income from Continuing Operations
¥26.7B
CAGR 3-Years
43%
CAGR 5-Years
-4%
CAGR 10-Years
3%
Takeda Pharmaceutical Co Ltd
TSE:4502
Income from Continuing Operations
¥144.2B
CAGR 3-Years
-27%
CAGR 5-Years
1%
CAGR 10-Years
3%
Daiichi Sankyo Co Ltd
TSE:4568
Income from Continuing Operations
¥201B
CAGR 3-Years
39%
CAGR 5-Years
16%
CAGR 10-Years
12%
Otsuka Holdings Co Ltd
TSE:4578
Income from Continuing Operations
¥141.7B
CAGR 3-Years
-4%
CAGR 5-Years
11%
CAGR 10-Years
-1%
Chugai Pharmaceutical Co Ltd
TSE:4519
Income from Continuing Operations
¥326.4B
CAGR 3-Years
16%
CAGR 5-Years
27%
CAGR 10-Years
18%
Astellas Pharma Inc
TSE:4503
Income from Continuing Operations
¥17B
CAGR 3-Years
-48%
CAGR 5-Years
-40%
CAGR 10-Years
-15%

See Also

What is Santen Pharmaceutical Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
26.7B JPY

Based on the financial report for Mar 31, 2024, Santen Pharmaceutical Co Ltd's Income from Continuing Operations amounts to 26.7B JPY.

What is Santen Pharmaceutical Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
3%

The average annual Income from Continuing Operations growth rates for Santen Pharmaceutical Co Ltd have been 43% over the past three years , -4% over the past five years , and 3% over the past ten years .